Eli Lilly and Co (LLY)
776.75
-4.35
(-0.56%)
USD |
NYSE |
May 01, 16:00
777.77
+1.02
(+0.13%)
Pre-Market: 07:28
Eli Lilly Accounts Receivable (Quarterly): 7.886B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 7.886B |
December 31, 2023 | 9.090B |
September 30, 2023 | 8.167B |
June 30, 2023 | 7.516B |
March 31, 2023 | 7.526B |
December 31, 2022 | 6.896B |
September 30, 2022 | 6.715B |
June 30, 2022 | 6.364B |
March 31, 2022 | 6.322B |
December 31, 2021 | 6.673B |
September 30, 2021 | 5.914B |
June 30, 2021 | 5.829B |
March 31, 2021 | 5.593B |
December 31, 2020 | 5.875B |
September 30, 2020 | 4.887B |
June 30, 2020 | 4.829B |
March 31, 2020 | 5.106B |
December 31, 2019 | 4.547B |
September 30, 2019 | 4.442B |
June 30, 2019 | 4.612B |
March 31, 2019 | 4.200B |
December 31, 2018 | 4.594B |
September 30, 2018 | 4.859B |
June 30, 2018 | 4.823B |
March 31, 2018 | 4.495B |
Date | Value |
---|---|
December 31, 2017 | 4.546B |
September 30, 2017 | 4.401B |
June 30, 2017 | 4.350B |
March 31, 2017 | 4.017B |
December 31, 2016 | 4.029B |
September 30, 2016 | 3.848B |
June 30, 2016 | 3.948B |
March 31, 2016 | 3.623B |
December 31, 2015 | 3.513B |
September 30, 2015 | 3.402B |
June 30, 2015 | 3.349B |
March 31, 2015 | 3.142B |
December 31, 2014 | 3.235B |
September 30, 2014 | 3.054B |
June 30, 2014 | 3.188B |
March 31, 2014 | 3.003B |
December 31, 2013 | 3.434B |
September 30, 2013 | 3.445B |
June 30, 2013 | 3.579B |
March 31, 2013 | 3.440B |
December 31, 2012 | 3.336B |
September 30, 2012 | 3.268B |
June 30, 2012 | 3.182B |
March 31, 2012 | 3.402B |
December 31, 2011 | 3.598B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
4.442B
Minimum
Sep 2019
9.090B
Maximum
Dec 2023
6.240B
Average
6.118B
Median
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 7.268B |
Madrigal Pharmaceuticals Inc | -- |
Vertex Pharmaceuticals Inc | 1.563B |
Viking Therapeutics Inc | -- |
Moderna Inc | 892.00M |